Psychiatry 92 , 950955 (2021)
Figure 3 (A) intracellular carnitine in PBMC relative to plasma levels, (B) intracellular BB in PBMC relative to plasma levels, (C) intracellular carnitine in erylysate relative to plasma levels, (D) intracellular BB in erylysate relative to plasma levels determined by tandem mass spectrometry
Higher concentrations (10mg/mL or greater) reduce injection volume but amplify measurement erroreach 0.01mL syringe increment represents 100mcg peptide, introducing 2040% relative error for sub-250mcg doses
The TGA reports a number of adverse events and other concerns received for unapproved peptide products, which include: severe allergic reactions, requiring doses of adrenaline and hospitalisation systemic inflammatory response syndrome (SIRS) (severe inflammation in the body), requiring hospital management generalised hypersensitivity symptoms such as fullbody intense itching, palpitations, pain and sweating wide ranging body side effects, including insomnia, blurred vision, extreme tiredness, flulike illness, joint pain and skin sensitivity musculoskeletal injuries, including plantar fasciitis and Achilles tendinitis, and poor product quality, including unsealed packaging from an online supplier
